Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis

医学 肝细胞癌 内科学 实体瘤疗效评价标准 阿替唑单抗 贝伐单抗 胃肠病学 不利影响 进行性疾病 阶段(地层学) 肿瘤科 癌症 化疗 无容量 免疫疗法 古生物学 生物
作者
Atsushi Hiraoka,Takashi Kumada,Toshifumi Tada,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki
出处
期刊:Hepatology Research [Wiley]
卷期号:52 (3): 308-316 被引量:55
标识
DOI:10.1111/hepr.13734
摘要

BACKGROUND/AIM: Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) as a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined the therapeutic efficacy of atezolizumab plus bevacizumab combination therapy (Atez/Bev) in such cases. This study aimed to elucidate the therapeutic response of Atez/Bev in u-HCC patients classified as UT-7 out/multiple. MATERIAL/METHODS: From September 2020 to September 2021, 95 u-HCC Japanese patients classified as UT-7 out/multiple/Child-Pugh A were enrolled from 21 institutions (median age 76 years, males 73, Child-Pugh 5:6 = 68:27, TNM stage II:III = 17:78). Therapeutic response was retrospectively evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1 and modified RECIST (mRECIST). RESULTS: Atez/Bev was given as first-line treatment to 52 (54.7%). Objective response rate (ORR)/disease control rate (DCR) at six weeks of RECIST and mRECIST were 17.7%/84.7% and 42.5%/86.2%, respectively. Median PFS was 8.0 months (median observation period: 6.0 months). Child-Pugh A/modified Albumin-bilirubin grade (mALBI) 1 and 2a at baseline, 3, 6, and 9 weeks, were 100%/69.4%, 89.8%/57.3%, 94.8%/65.3%, and 91.4%/60.0%, respectively. Among adverse events (any-grade, >10%) during the present observation period, general fatigue was most frequent (23.2%), followed by urine protein (21.1%), appetite loss (20.0%), and hypertension (13.7%). CONCLUSION: Atez/Bev treatment showed favorable therapeutic response with less influence on hepatic function, suggesting it as a useful therapeutic option for patients with such condition.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桐桐的应助被yin采纳,获得10
刚刚
皮皮完成签到,获得积分10
刚刚
小刘发布了新的文献求助10
1秒前
Yue发布了新的文献求助10
1秒前
慕晓完成签到,获得积分20
1秒前
1秒前
abfs完成签到,获得积分10
1秒前
完美世界的应助被静心采纳,获得10
1秒前
369ninja发布了新的文献求助10
2秒前
2秒前
2秒前
糖糖的冰镇啤酒完成签到,获得积分10
2秒前
luochenglin完成签到,获得积分10
2秒前
ling完成签到,获得积分10
2秒前
2秒前
小二郎的应助被mkl采纳,获得10
2秒前
研友_VZG7GZ的应助被youbei采纳,获得10
2秒前
whyritoday发布了新的文献求助10
3秒前
默默的橘子完成签到 ,获得积分10
3秒前
羊羊羊完成签到,获得积分10
3秒前
情怀的应助被inghai采纳,获得10
3秒前
JamesPei的应助被123456789采纳,获得10
3秒前
00完成签到,获得积分10
3秒前
4秒前
cheng关注了科研通微信公众号
4秒前
4秒前
4秒前
4秒前
酷波er的应助被长亭采纳,获得10
4秒前
Stayup_o9完成签到 ,获得积分10
4秒前
LJC发布了新的文献求助10
5秒前
July完成签到,获得积分10
5秒前
大力依珊完成签到,获得积分10
5秒前
Kerizn发布了新的文献求助10
5秒前
华仔的应助被里哈哈采纳,获得10
6秒前
1111111111111完成签到,获得积分10
6秒前
动听无声发布了新的文献求助10
6秒前
天真南风完成签到,获得积分10
6秒前
Maestro_S的应助被皮卡路采纳,获得10
6秒前
yy32323完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185